Clinuvel Pharmaceuticals (ASX:CUV) said its new drug submission to Health Canada for its photoprotective therapy Scenesse was validated and accepted for review ahead of the regulator's target validation window, according to a Monday filing with the Australian bourse.
Scenesse was designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria an inherited metabolic disorder.
The submission is now under review by Health Canada's Health Products and Food Branch, which has a 300-day target to complete its evaluation and issue a marketing authorization decision, the filing said. A decision is expected by the fourth quarter of 2025.
Clinuvel Pharmaceuticals shares rose nearly 1% in morning trade Monday.
Price (AUD): $11.90, Change: $+0.11, Percent Change: +0.93%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。